Slug-based epithelial-mesenchymal transition gene signature is associated with prolonged time to recurrence in glioblastoma by Wei-Yi Cheng et al.
1 
Slug-based epithelial-mesenchymal transition gene signature 
is associated with prolonged time to recurrence in 
glioblastoma. 
 
Wei-Yi Cheng
1,7
, Jessica J Kandel
2,3,4
, Darrell J Yamashiro
2,4,5
, Peter Canoll
5,6
 and 
Dimitris Anastassiou
1,7§  
 
1
Center for Computational Biology and Bioinformatics, Columbia University, New York,       
NY, USA 
2
Institute for Cancer Genetics, Columbia University, New York, NY, USA 
3
Department of Surgery, Columbia University, New York, NY, USA 
4
Department of Pediatrics, Columbia University, New York, NY, USA 
5
Department of Pathology and Cell Biology, Columbia University, New York, NY, USA 
6
Columbia Stem Cell Initiative, Columbia University, New York, NY, USA 
7
Department of Electrical Engineering, Columbia University, New York, NY 10027 
 
§
Corresponding author 
 
Email addresses: 
 
WC:  wc2302@columbia.edu  
JJK:  jjk47@columbia.edu  
DJY:  dy39@columbia.edu 
PC:  pc561@columbia.edu 
DA:  da8@columbia.edu 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
54
4.
1 
: P
os
te
d 
18
 O
ct
 2
01
1
2 
Abstract 
Background 
We previously identified a precise stage-associated gene expression signature of coordinately 
expressed genes, including the transcription factor Slug (SNAI2) and other 
epithelial-mesenchymal transition (EMT) markers, present in samples from publicly available 
gene expression datasets in multiple cancer types. The expression levels of the co-expressed 
genes vary in a continuous and coordinate manner across the samples, ranging from absence of 
expression to strong co-expression of all genes. These data suggest that tumor cells may pass 
through an EMT-like process of mesenchymal transition to varying degrees.   
Findings 
Here we show that this signature in glioblastoma multiforme (GBM) is associated with time to 
recurrence following initial treatment. By analyzing data from The Cancer Genome Atlas 
(TCGA), we found that GBM patients who responded to therapy and had long time to recurrence 
had low levels of the signature in their tumor samples (P = 3×10
-7
). We also found that the 
signature is strongly correlated in gliomas with the putative stem cell marker CD44, and is highly 
enriched among the differentially expressed genes in glioblastomas vs. lower grade gliomas.  
Conclusions  
Our results suggest that long delay before tumor recurrence is associated with absence of the 
mesenchymal transition signature, raising the possibility that inhibiting this transition might 
improve the durability of therapy in glioma patients.   
 
Keywords:  
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Findings 
We recently identified [1] a precise multi-cancer gene expression signature, consisting of a set of 
genes that are coordinately overexpressed only in samples of cancer that have exceeded a 
particular stage, specific to each cancer type. Table 1 contains a list of the 64 genes 
corresponding to the top 100 probe sets (as presented in Table 4 of [1]) of the signature. The 
signature contains numerous epithelial-mesenchymal transition (EMT) markers [2, 3], such as 
the EMT-inducing transcription factor Slug (SNAI2), as well as COL5A2, FAP, POSTN, 
COL1A2, COL3A1, FBN1, TNFAIP6, MMP2, GREM1, BGN, CDH11, SPOCK1, DCN, 
COPZ2, THY1, PCOLCE, PRRX1, PDGFRB, SPARC, INHBA, COL6A2, FN1, ACTA2. 
However, the signature is also present even in some nonepithelial cancers, such as 
neuroblastoma and Ewing’s sarcoma.  In each dataset, the expression level of the co-expressed 
genes varies in a continuous manner across the samples. In a recent experiment we also 
confirmed that most of the genes of the signature are expressed in some xenografted human 
cancer cells themselves in vivo, but not in the host mouse cells. These results indicate that cancer 
cells can pass through a transition process to a more mesenchymal state, to varying degrees 
ranging from total lack of expression to strong co-expression of the genes of the signature.   
 
The average expression level of these 64 genes can be thought of as the expression level of a 
metagene representing the signature. We hypothesized that this value is associated with clinical 
data in glioblastoma multiforme (GBM) for which there is rich such data available at The Cancer 
Genome Atlas (TCGA). We found that there was indeed strong association of the metagene with 
the phenotype “Days to Tumor Recurrence,” defined as the time period from initial treatment 
until the date of the diagnosis or recognition of the presence and nature of the return of signs and 
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symptoms of cancer following a period of improvement. Patients who did not experience 
improvement after therapy have a “null” entry in the corresponding field. 
 
Figure 1 shows a scatter plot in which each of the 99 samples for which the “Days to Tumor 
Recurrence” phenotype has a non-null entry is represented by a dot indicating the expression 
level of the metagene and the number of days to tumor recurrence. The figure reveals that, within 
the group of patients who experienced improvement after therapy, the eight patients whose 
tumors recurred more than three years following therapy have very low values of the expression 
of the metagene. Figure 2 shows a heat map of the 64 genes, where the samples are ranked in 
terms of the expression of the metagene and the eight patients for which time to recurrence was 
more than three years are highlighted in green. The rank sum for these eight patients is 
1+2+6+7+9+11+16+18 = 70. This rank sum can be used as a measure of the association of the 
lack of expression of a gene with the “Days to Tumor Recurrence” phenotype. To evaluate its 
statistical significance, we randomly permuted the phenotype among the 99 samples and 
recalculated the rank sum, which is equivalent to finding the sum of eight randomly picked 
numbers from 1 to 99. This sum will be less than or equal to 70 very rarely. The estimated P 
value after doing 10 million permutations is 3×10
-7
.  
 
We then used the same metric (rank sum) to identify which, among the individual 64 genes of 
Table 1 defining the metagene have the best score, expecting that some of them would have rank 
sum lower than 70. Remarkably, the best scoring gene was COL5A1 with rank sum equal to 78 
followed by COL6A2 with rank sum equal to 82. In other words, the score of the metagene is 
significantly better than that of any of its individual component genes. Even more strikingly, 
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after doing exhaustive search among all 12,042 genes, the top ranked gene (EFEMP2) had rank 
sum equal to 75, still worse than that (70) of  the metagene. These results suggest that the 
signature identified in [1] comprises a synergistic collection of genes corresponding to a 
biological mechanism of mesenchymal transition, which, when absent, is associated with 
increased time period to tumor recurrence in GBM.   
 
Table 2 shows a listing of the top 30 individual genes in terms of their rank sum for the “Days to 
Tumor Recurrence” phenotype. Nine out of these 30 genes, highlighted in Table 2, are among 
the 64 genes of Table 1, demonstrating the strong enrichment (P = 3×10
-14
) of EMT markers in 
this unbiased collection of genes associated with the phenotype. 
 
While all cases in the TCGA dataset have been diagnosed as glioblastoma, the delayed 
recurrence in these eight cases is more a characteristic of lower grade gliomas. Therefore, we 
investigated whether lower grade gliomas are also characterized by lower levels of the signature 
by analyzing the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt) dataset, 
which included gene expression from both glioblastoma as well as various types of lower grade 
gliomas. Table 3 demonstrates that, indeed, there is strong enrichment (seven of the 64 genes in 
Table 1 are among the top-ranked 30 differentially expressed genes, P = 10
-13
). Furthermore, we 
found strong correlation between the expression levels of the metagene and the cancer stem cell 
marker CD44 (P = 5×10
-56
 based on fitting Pearson correlation to t-distribution). Figure 3 shows 
the corresponding scatter plot. Recent studies have shown that high levels of CD44 are expressed 
in cancer stem cells isolated from several different types of tumors [4], although this concept is 
still in evolution, and CD44 is also expressed in a variety of other cell types. CD44 has been 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
54
4.
1 
: P
os
te
d 
18
 O
ct
 2
01
1
6 
found in a cell population enriched for glioma stem cells [5]. It is also widely expressed in 
glioblastoma, and increased levels are associated with glioma progression and resistance to 
therapy [6]. 
 
Because gliomas are not epithelial cancers, and the signature has also been found in other 
nonepithelial cancers, such as neuroblastoma and Ewing’s sarcoma, the signature represents 
more general biological process of mesenchymal transition. 
 
It has recently been suggested that “stemness” in tumor cells (characterized by the ability to both 
self-renew as well as generate differentiated descendants) may be intimately interconnected with 
passing through an EMT.  For example, EMT in some models was found to generate cells with 
properties of stem cells [7-11]. Notably, it has been shown that stem-like cells isolated from 
human breast cancer co-express high levels of CD44 and high levels of mesenchymal markers, 
including Slug [7]. Furthermore, inducing EMT in immortalized human mammary epithelial 
cells leads to high levels of CD44 expression in the mesenchymal-like cells [7]. Drug resistance 
has also been linked to the presence of cancer stem cells [9, 11-13], supporting the notion that 
cancer stem cells may be responsible for recurrence after therapeutic intervention. Therefore, and 
given the strong correlation of the mesenchymal transition signature with CD44, one possible 
explanation for the absence of the mesenchymal transition signature in patients with 
exceptionally long time to recurrence may be due to a corresponding lack of stemness in the 
cancer cells of these patients making it more unlikely for the cancer to recur following treatment.   
An alternative explanation for the observed association may be provided by the transformation 
towards a more mesenchymal phenotype.                               
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The signature has been found in multiple cancers [1] and, among its component genes, Slug is 
the only consistently upregulated EMT-inducing transcription factor. Slug has also recently been 
found to be associated with invasiveness in glioma [14], consistent with the results presented 
here. Furthermore, when we ranked all genes in terms of their correlation (using the measure of 
mutual information [15]) of their expression with that of Slug in the 99 samples that we analyzed 
here, we found that, remarkably, the top eight entries (COL6A3, COL3A1, LUM, COL5A1, 
COL1A2, COL6A2, COL1A1, PCOLCE) were all genes included in both Tables 1 as well as 
Table 2, further supporting the hypothesis that Slug might be a master regulator of the biological 
mechanism responsible for the signature. 
 
The same signature was also found to be predictive of neoadjuvant therapy in breast cancer - see, 
e.g. additional file 6 of [1], in which 7 of 8 samples in the cluster on the left side of the heat map 
(with low levels of the signature) had good response to therapy, while 12 out of 14 samples in 
the second cluster (with high levels of the signature) were resistant.   
 
Analysis of gene expression data has resulted in classification into various subtypes of 
glioblastomas [16, 17], also present in lower grade gliomas [18], with distinct features, each of 
which is characterized by the presence of particular genes. Interestingly, CD44 was found 
enriched either in the mesenchymal subtypes or in glioblastomas in all these cases. The feature of 
our current results, however, is that the mesenchymal transition signature used in this paper 
reflects a biological process applicable to multiple cancer types, as it was derived by analyzing 
its presence in many different cancers [1], as opposed to using classification methods on glioma 
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samples alone to identify subtypes. Furthermore, the association with the phenotype is found in 
the absence, rather than the presence, of the signature.  
 
The observations that (a) all GBM patients with exceptionally long time to recurrence had 
extremely low levels of the mesenchymal transition gene signature, and (b) the mesenchymal 
transition signature is strongly enriched among the genes underexpressed in lower grade gliomas 
as compared to glioblastomas, suggest that targeting the underlying biological mechanism might 
supply a novel approach for adjuvant treatment of gliomas. Further, the ability to precisely 
identify components of the gene signature provides unique opportunities for identifying potential 
targets for such treatment.   
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Figure captions 
 
 
Figure 1.  Scatter plot for Days to Tumor Recurrence vs. expression of the mesenchymal 
transition metagene 
 
 
Each dot in the scatter plot represents one of the 99 patients for which the “Days to Tumor 
Recurrence” phenotype has a non-null entry. The horizontal axis measures the average of the 
RMA-normalized expression levels of the 64 genes shown in Table 1. The vertical axis measures 
the days to tumor recurrence and the horizontal dotted line is drawn at the 3 year cutoff point. 
 
 
Figure 2. Heat map of the components of the mesenchymal transition metagene in glioblastoma 
 
 
The 99 samples are ranked in terms of the average expression level of the genes shown in 
Table 1. The eight patients for which time to recurrence was more than three years are 
highlighted in green at the 1
st
, 2
nd
, 6
th
, 7
th
, 9
th
, 11
th
, 16
th
, and 18
th
 position, resulting in the rank 
sum of 70.  
 
Figure 3. Scatter plot for the expression levels of CD44 vs. the mesenchymal transition 
metagene 
 
Each dot in the scatter plot represents a glioma sample from the NCI Repository for Molecular 
Brain Neoplasia Data (Rembrandt) dataset. Dots are color coded red for glioblastomas and blue 
for lower grade gliomas. Expression levels are RNA normalized. 
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Figure 1.  Scatter plot for Days to Tumor Recurrence vs. expression of the mesenchymal 
transition metagene 
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Figure 2. Heat map of the components of the mesenchymal transition metagene in glioblastoma 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
54
4.
1 
: P
os
te
d 
18
 O
ct
 2
01
1
14 
Figure 3.  Scatter plot for the expression levels of CD44 vs. the mesenchymal transition 
metagene 
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Table 1. Genes comprising the Slug-based EMT signature. 
 
 
Rank Gene Rank Gene 
1 COL11A1 33 LOXL2 
2 THBS2 34 COL6A3 
3 COL10A1 35 MXRA5 
4 COL5A2 36 MFAP5 
5 INHBA 37 NUAK1 
6 LRRC15 38 RAB31 
7 COL5A1 39 TIMP3 
8 VCAN 40 CRISPLD2 
9 FAP 41 ITGBL1 
10 COL1A1 42 CDH11 
11 MMP11 43 TMEM158 
12 POSTN 44 SPOCK1 
13 COL1A2 45 SFRP4 
14 ADAM12 46 SERPINF1 
15 COL3A1 47 DCN 
16 LOX 48 C7orf10 
17 FN1 49 COPZ2 
18 AEBP1 50 NOX4 
19 SULF1 51 EDNRA 
20 FBN1 52 ACTA2 
21 ASPN 53 PDGFRB 
22 SPARC 54 RCN3 
23 CTSK 55 SNAI2 
24 TNFAIP6 56 C1QTNF3 
25 HNT 57 COMP 
26 EPYC 58 LGALS1 
27 MMP2 59 THY1 
28 PLAU 60 PCOLCE 
29 GREM1 61 COL6A2 
30 BGN 62 GLT8D2 
31 OLFML2B 63 NID2 
32 LUM 64 PRRX1 
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Table 2. Top genes in terms of the rank sum for the “Days to Tumor Recurrence” phenotype 
 
 
EFEMP2 75                   
CD248  78      
COL5A1 78      
IL7R  78      
MYH9  81    
COL6A2 82      
FLNC  82      
AKAP12 87      
TREM1 87      
COL1A2 88      
PSCDBP 88      
S100A8 91      
CLEC2B 92      
GLIPR1 98      
COL6A3 99      
THBD  99         
CALD1 102      
CD163  102      
EFEMP1 102      
ENPEP 103      
PCOLCE 103      
TMEM5 103      
SDCBP 104      
COL1A1 105      
LUM  105      
TNC  106        
VNN1  106      
CARS  107      
FN1  107      
COL3A1 108    
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Table 3. Top differentially expressed gene in glioblastomas vs. lower grade gliomas  
 
 
Probe Set ID Gene Symbol Fold Change 
209395_at CHI3L1 10.36 
202718_at IGFBP2 6.07 
210809_s_at POSTN 5.77 
201666_at TIMP1 5.70 
1556499_s_at COL1A1 5.69 
215076_s_at COL3A1 5.59 
202404_s_at COL1A2 5.17 
206157_at PTX3 4.90 
201012_at ANXA1 4.87 
202237_at NNMT 4.82 
211527_x_at VEGFA 4.73 
221898_at PDPN 4.65 
202912_at ADM 4.65 
215446_s_at LOX 4.43 
202345_s_at FABP5 4.41 
226517_at BCAT1 4.30 
203729_at EMP3 4.14 
202018_s_at LTF 4.05 
227697_at SOCS3 3.96 
211981_at COL4A1 3.64 
209156_s_at COL6A2 3.62 
201505_at LAMB1 3.59 
226237_at 226237_at 3.59 
236028_at IBSP 3.57 
201744_s_at LUM 3.53 
225681_at CTHRC1 3.52 
203645_s_at CD163 3.51 
211964_at COL4A2 3.49 
201110_s_at THBS1 3.44 
208949_s_at LGALS3 3.42 
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